Strength of Wisconsin Biohealth

Digital Health:

Where digital technology meets health solutions. Digital health is empowering patients and healthcare systems to provide personalized care, improve quality, and reduce costs. Digital health is Wisconsin’s newest and fastest growing sector.

Medical Device & Diagnostics:

The medical device and diagnostics industry continues to grow and thrive in Wisconsin, with medical device companies ranging from start-ups to corporate powerhouses choosing to call Wisconsin home. Two-thirds of Wisconsin’s bioscience-related patents filed from 2014-2017 fall in this sector, accounting for 1,862 medical & surgical device patents.

Health Research Institutes:

Wisconsin boasts some of the nations top research institutes. Wisconsin research institutes received $424.9 million in NIH funding and reported $914 million in academic biosciences R&D expenditures in 2017 alone.

Biotech & Biopharma:

From therapeutic and drug development to translational and integrated science, Wisconsin has it all. Accounting for one of the states’s largest economic drivers, biotech and biopharma continue to flourish in Wisconsin. A leading employer throughout the state, this segment boasts a direct-effect employment multiplier of 4.78.

Wisconsin: A National Hub for Biomanufacturing

Top Talent. Top Resources. Top Industry.

Innovation. Right here, in Wisconsin.

The U.S. Food and Drug administration has given a key approval to Germantown medical device startup Somna Therapeutics LLC.

Somna has been cleared to sell its Reza Band device—which reduces laryngopharyngeal reflux symptoms—over the counter. The Reza Band will no longer require a prescription, and consumers can buy it directly off the company’s website for $169. Read more here.

Cellectar Biosciences (Nasdaq:CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announces that the U.S. Food and Drug Administration (FDA) Office of Orphan Products Development has granted Orphan Drug Designation to CLR 131, the company’s lead Phospholipid Drug Conjugate™ (PDC) product candidate, for the treatment of rhabdomyosarcoma, a rare pediatric cancer. Read more here.

NorthStar Medical Radioisotopes, LLC, (NorthStar) a company involved in the production and distribution of radioisotopes used for medical imaging, today announced that the U.S. Food and Drug Administration (FDA) has approved the RadioGenixTM System, an innovative, high tech radioisotope separation platform indicated for use in producing the widely used medical radioisotope technetium-99 (Tc-99m) from NorthStar’s non-uranium based molybdenum-99 (Mo-99).

There has been no U.S. production of Mo-99, the parent isotope of Tc-99m, for more than 25 years. The supply of Mo-99 has been subject to frequent and sometimes prolonged interruptions, disrupting and often delaying the diagnosis and treatment of patients in need of medically important diagnostic tests that require the use of this radioisotope. Furthermore, current bulk production of Mo-99 is based on enriched uranium, which poses significant environmental concerns. Read more here.

FluGen, Inc. announced today that the first subject has been dosed in a clinical study in Belgium which will challenge subjects with an influenza virus genetically mismatched by six years from the influenza strain utilized in the vaccine.

“If successful, the results from this challenge study of FluGen’s M2SR vaccine would represent a significant step forward in bringing a novel influenza vaccine to patients; and which responds to the need for broader protection and increased effectiveness, as compared to existing influenza vaccine options,” said Paul Radspinner, chief executive officer of FluGen. Read more here.

The Morgridge Institute for Research is launching the John W. and Jeanne M. Rowe Center for Research in Virology, a new transformative research initiative made possible by the philanthropic support of John and Jeanne Rowe.

The center builds upon the virology research at the Morgridge Institute led by Paul Ahlquist, the John W. and Jeanne M. Rowe Chair in Virology, and also comprises two additional Morgridge investigators and University of Wisconsin-Madison faculty, including Tony Gitter who specializes in computational biology. Read more here.

QUALITY OF LIFE

biohealth3

Welcome home: Wisconsin is home to endless outdoor activities throughout all seasons, growing tech & health industries, and a top-tier university system making our home the 8th state in the 2016 Quality of Life list by Forbes.

COLLABORATION

biohealth2

When industries and instituitions converge and great minds connect, big things happen. Read about collaboration success stories that started right here in Wisconsin and learn how to start your own collaboration story.

TALENT

biohealth1

Wisconsin boasts both a world-class university system and top-tier talent.  Madison ranks 1st for STEM college graduates. Search our career center for opportunites or find your future hire here:

2015 Wisconsin Bioscience Economic Development Report: Energizing Wisconsin's Economy

READY TO JOIN THE MOVEMENT?

Contact our team member Kate at krodgers@bioforward.org to learn how to get involved!